{"id":"cjc-1295","name":"CJC-1295","aliases":["CJC-1295 DAC","modified GRF(1-29)","tesamorelin's cousin"],"url":"https://lyoresearch.com/compounds/cjc-1295","class":{"id":"ghrh-analogues","name":"GHRH analogues","url":"https://lyoresearch.com/classes/ghrh-analogues"},"summary":"CJC-1295 is a modified growth-hormone-releasing hormone fragment engineered to bind albumin so that it lasts days rather than minutes. Early human trials showed substantial, sustained rises in growth hormone and IGF-1 with weekly dosing. Development was discontinued and no trial has measured whether that translates into any clinical outcome. It is not approved anywhere and is banned in sport.","overall_grade":"C","overall_grade_meaning":"weak human evidence","human_trials":"Early-phase only; programme discontinued","regulatory_status":"Not approved","molecule":{"formula":"C165H269N47O46","molecular_weight":"3647.2","cas":"446262-90-4","pubchem_cid":91971820,"note":"Record is CJC-1295 with DAC"},"pharmacokinetics":{"basis":"human","route":"Subcutaneous (healthy adults; the DAC form)","half_life":"About 6–8 days (CJC-1295 with DAC). No human data for the 'no-DAC' form","licensed_regimen":null,"product":null,"source":{"title":"Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91:799–805","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/"}},"outcomes":[{"outcome":"Growth hormone / IGF-1 elevation","grade":"B","grade_meaning":"probable, not settled","effect_size":"large","adverse":false,"human_studies":"Phase 1 / early phase 2","evidence":"Weekly dosing produced sustained multi-fold GH increases and IGF-1 elevations over weeks in healthy adults — a large, reproducible effect on the marker.","references":[{"citation":"Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","where":"J Clin Endocrinol Metab, 2006;91:799–805","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/"}],"verbatim":{"text":"After a single injection of CJC-1295, there were dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 d or more and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 d.","citation":"Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/"}},{"outcome":"Body composition","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None","evidence":"No trial has measured muscle or fat change.","references":[]},{"outcome":"Any clinical outcome","grade":"D","grade_meaning":"no human evidence","effect_size":"not measurable","adverse":false,"human_studies":"None","evidence":"The programme was discontinued before efficacy trials in any indication.","references":[]},{"outcome":"Safety in humans","grade":"C","grade_meaning":"weak human evidence","effect_size":"not measurable","adverse":true,"human_studies":"Early-phase only","evidence":"Short early-phase exposure only. Long-term safety of sustained IGF-1 elevation is unstudied.","references":[]}],"regions":[{"region":"European Union","status":"Unauthorised medicinal product","note":"No marketing authorisation in any member state. Supplying it for human use is an offence under national medicines law; 'research use only' labels do not change that."},{"region":"United States","status":"Not approved; compounding barred","note":"The advisory committee excluded all five CJC-1295 forms on 4 December 2024; the nomination is listed as withdrawn since April 2026. Sold otherwise as an unapproved 'research chemical'."},{"region":"United Kingdom","status":"Unlicensed medicine","note":"Not licensed by the MHRA. Selling or supplying it is an offence under the Human Medicines Regulations 2012; importing a small quantity purely for personal use is not itself an offence, but consignments are seized."},{"region":"Australia","status":"Schedule 4, unapproved","note":"Prescription-only substance not on the ARTG. Obtainable only on prescription (compounded or imported under the Personal Importation Scheme with a prescription). Named in the TGA's April 2026 advisory. Named in NSW law as a prescribed restricted substance."},{"region":"Canada","status":"Not authorised","note":"No Drug Identification Number; selling it is illegal. Among the products Health Canada seized from a domestic vendor in August 2025. Residents cannot import prescription drugs by mail."},{"region":"Sport (WADA)","status":"Prohibited at all times","note":"GHRH analogue: S2.2.4."}],"faq":[{"q":"Does CJC-1295 build muscle?","a":"Unknown. It raises growth hormone and IGF-1 substantially — that part is well documented in early trials. Whether that changes muscle or fat has never been measured in a trial."},{"q":"What is the difference between CJC-1295 with and without DAC?","a":"The DAC (drug affinity complex) version binds to albumin and lasts about a week. Without DAC it is essentially modified GRF(1-29), lasting around half an hour. They are sold under the same name."},{"q":"Why was development stopped?","a":"The programme was discontinued after early-phase work, without efficacy trials in any indication."}],"references":[{"cite":"Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults.","where":"J Clin Endocrinol Metab, 2006;91:799–805","url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","note":"The early-phase human pharmacology; no outcome endpoints."}],"last_reviewed":"2026-09-02","literature_searched_to":"2026-09-02","changelog":[{"date":"2026-09-02","note":"Initial publication. Hormone effect graded B; all downstream outcomes D."}],"license":"CC BY 4.0 — cite as “LYO Research” with a link.","methodology":"https://lyoresearch.com/methodology"}